Exelixis | EXEL - Créances Commerciales





Créances Commerciales Changement Date
Acadia Pharmaceuticals USD 148.38M 153K 2026-03
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Akebia Therapeutics USD 47.03M 19.19M 2025-12
Amgen USD 9.14B 432M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
Bayer EUR 18.55B 4.36B 2026-03
BioMarin Pharmaceutical USD 903.91M 4.3M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Cytokinetics USD 6.83M 10.94M 2026-03
Eisai JPY 227B 22.05B 2026-03
Eli Lilly USD 21.18B 1.02B 2026-03
Esperion Therapeutics USD 140.19M 21.21M 2025-12
Exelixis USD 328.95M 42.03M 2026-03
Genmab DKK 1.17B 119M 2025-12
Glaxosmithkline GBP 10.45B 707.81M 2025-12
Incyte USD 1.05B 27.09M 2026-03
Ionis Pharmaceuticals USD 74M 8M 2026-03
MacroGenics USD 13.37M 55.86M 2025-12
Merck USD 11.78B 345M 2025-12
Moderna USD 71M 113M 2026-03
Nektar Therapeutics USD 1.78M 1.12M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Novartis USD 9.6B 2.69B 2026-03
Pfizer USD 16.17B 332M 2026-03
Puma Biotechnology USD 28.1M 3.52M 2024-06
Sanofi EUR 397M 186.13M 2025-12
Takeda JPY 876.35B 118.43B 2026-03
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Xencor USD 12M 17.3M 2026-03